Biostatistics Support
Gain stronger clarity in communication with the methodical biostatistics CRO services needed for drug development today!
The MMS team are all superstars! You have delivered to timelines throughout, and we really appreciate it. Thank you!
Expertise and regulatory insights set MMS apart.
Expert biostatisticians at MMS hold the trust of leading pharmaceutical and biotechnology Sponsors. Our biostatistics team has an incomparable, industry-educated skill set and end-game experience to provide support in:
- Sample size calculations,
- Randomization schedules,
- Statistical analysis plans (SAP),
- Data interpretation,
- Collaborative solution finding on data/analysis related hurdles, and much more.
When Sponsors engage an MMS biostatistician, they are guaranteed clarity in understanding the statistical rationale and excellent communication with all team members, including programmers, data management, data scientists, medical writers, and clinicians.
The success of a clinical trial depends on the strength and knowledge of the biostatistics lead. When supporting Sponsors with statistical analyses and protocol development for global health authority responses and/or publication support, the biostatisticians at MMS are experienced, attentive, methodical, and intuitive.
What Differentiates MMS From Other CROs?
responsive
MMS is more responsive, taking responsibility for the success of every project with consistent staff and proactive solutions that exceed the expectations of a CRO partner.
adaptable
MMS is more adaptable, knowing your satisfaction and top outcomes are dependent on our ability to remain nimble and make smart decisions based on scientifically-sound data.
focused
MMS is more focused, providing data-centric solutions and innovative technology and processes that help accelerate and de-risk the development and approval of your therapy.
Suggested For You
perspectives
December 11th, 2024
Why Emerging biotech companies are increasingly turning to Specialized Data CROs
regulatory intelligence
December 4th, 2024
FDA Issues Detailed Guidance on Development of Gene Therapy Products
news
December 4th, 2024
AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium
perspectives
November 26th, 2024
Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs
perspectives
November 21st, 2024
Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success
news
November 19th, 2024
MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year
perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar
news
November 8th, 2024
MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance
perspectives
November 6th, 2024
How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure
perspectives
October 29th, 2024
Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies
perspectives
October 22nd, 2024
Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development
perspectives
October 15th, 2024
Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens